Home > Analytics > BALAXI PHARMACEUTICALS

BALAXI PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM :      NSE : BALAXI    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Upward
Pledged Shares : None or < 25%
May 18,2024
Price(EOD): ₹ 654.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Trading
MCap: ₹ 720.06 Cr
Value of ₹ 1 Lac invested in BALAXI PHARMACEUTICALS
on May 20,2019 (price: ₹ 108.75)

₹ 1 L

₹ 6.02 L

1W : 7.2% 1M : 12.9% 1Y : 16.5%
COMMUNITY POLL
for BALAXI PHARMACEUTICALS
Please provide your vote to see the results
BALAXI PHARMACEUTICALS is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Best 1M Momentum Small Cap Stocks
Industry Peers & Returns1W1M1Y
BALAXI PHARMACEUTICALS 7.2% 12.9% 16.5%
ADANI ENTERPRISES 0.8% 1.3% 62.1%
REDINGTON -0.5% -4.5% 20.4%
HONASA CONSUMER -2.4% 6.2% NA
MMTC 5.4% 6.2% 147.3%
MSTC 14.8% 12.2% 211.4%
LLOYDS ENTERPRISES -0.8% 0.9% 291.1%
VERITAS (INDIA) 8.2% 3.2% 800.4%
NOVARTIS INDIA 6.5% 8.6% 58.6%

FUNDAMENTAL ANALYSIS OF BALAXI PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Dec2023, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 BALAXI is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF BALAXI PHARMACEUTICALS

 
Valuation Score
[As on : May 18,2024 ]

Ratio Consolidated
P/E
P/B
P/S
-138.44
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -5.22 Cr
[Latest Qtr - Dec2023 - Consolidated Results ]

4.19
P/B Calculated based on Book Value of Rs 172.58 Cr
[Latest Year - Mar2023 - Consolidated Results ]

2.76
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 262.14 Cr
[Latest Qtr - Dec2023 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 12% undervalued companies ! Discover More →

FAIR VALUE OF BALAXI PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
141%
125%
124%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF BALAXI PHARMACEUTICALS


Insights 💡 BALAXI is one of the top 36% companies with bullish price momentum currently! Discover More →

BALAXI PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF BALAXI PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2023
2022
2021
Avg_3yrs
0.13
0.03
0.08
0.08
0.07
0.03
0.06
0.05
[Last Annual Data : Mar2023]
Financial Ratios →

PLEDGED PROMOTER SHARES OF BALAXI PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Dec2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF BALAXI PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
11.08%
26.9%
-8.86%
-5.79%
-29.79%
-10.67%
35.6%
65.2%
QtrlyTrend
0
Latest Qtr: Dec2023
Quarterly Result Analysis →


BALAXI PHARMACEUTICALS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about BALAXI PHARMACEUTICALS


Is BALAXI PHARMACEUTICALS good for long term investment?

As on May 18,2024, the Fundamentals of BALAXI PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of BALAXI PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is BALAXI PHARMACEUTICALS UnderValued or OverValued?

As on May 18,2024, BALAXI PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of BALAXI PHARMACEUTICALS ?

As on May 18,2024, the Intrinsic Value of BALAXI PHARMACEUTICALS is Rs. 291.35 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 272.16
Fair Value [Median EV / Sales Model] : Rs. 291.35
Fair Value [Median Price / Sales Model] : Rs. 291.66
Estimated Median Fair Value of BALAXI PHARMACEUTICALS : Rs. 291.35

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is BALAXI PHARMACEUTICALS trading at a Premium or Discount?

As on May 18,2024, BALAXI PHARMACEUTICALS is trading at a Premium of 125% based on the estimates of Median Intrinsic Value!